Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S. Park SR, et al. Among authors: wright jj. Cancer Chemother Pharmacol. 2013 Apr;71(4):981-90. doi: 10.1007/s00280-013-2091-3. Epub 2013 Feb 13. Cancer Chemother Pharmacol. 2013. PMID: 23404627 Free PMC article. Clinical Trial.
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
Thomas RR, Dahut W, Harold N, Grem JL, Monahan BP, Liang M, Band RA, Cottrell J, Llorens V, Smith JA, Corse W, Arbuck SG, Wright J, Chen AP, Shapiro JD, Hamilton JM, Allegra CJ, Takimoto CH. Thomas RR, et al. Cancer Chemother Pharmacol. 2001 Sep;48(3):215-22. doi: 10.1007/s002800100329. Cancer Chemother Pharmacol. 2001. PMID: 11592343 Clinical Trial.
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Lara PN Jr, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: wright jj. Anticancer Drugs. 2005 Mar;16(3):317-21. doi: 10.1097/00001813-200503000-00011. Anticancer Drugs. 2005. PMID: 15711184 Clinical Trial.
A phase II study of perifosine in androgen independent prostate cancer.
Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL. Posadas EM, et al. Cancer Biol Ther. 2005 Oct;4(10):1133-7. doi: 10.4161/cbt.4.10.2064. Epub 2005 Oct 1. Cancer Biol Ther. 2005. PMID: 16138006 Free article. Clinical Trial.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL. Arlen PM, et al. J Urol. 2007 Oct;178(4 Pt 1):1515-20. doi: 10.1016/j.juro.2007.05.117. Epub 2007 Aug 16. J Urol. 2007. PMID: 17707059 Clinical Trial.
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, Wright JJ, Rosing DR, Sparreboom A, Figg WD, Steinberg SM. Schrump DS, et al. Among authors: wright jj. Clin Cancer Res. 2008 Jan 1;14(1):188-98. doi: 10.1158/1078-0432.CCR-07-0135. Clin Cancer Res. 2008. PMID: 18172270 Clinical Trial.
368 results